NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis $5.00 0.00 (0.00%) As of 05/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 2seventy bio Stock (NASDAQ:TSVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 2seventy bio alerts:Sign Up Key Stats Today's Range$5.00▼$5.0050-Day Range$4.98▼$5.0052-Week Range$2.29▼$5.30VolumeN/AAverage Volume642,107 shsMarket Capitalization$266.15 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Read More Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TSVT Stock News Headlines2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbMay 7, 2025 | businesswire.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTApril 16, 2025 | businesswire.comBanks aren’t ready for this altcoin—are you?In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?July 2 at 2:00 AM | Crypto 101 Media (Ad)2seventy Bio reports Q4 EPS (37c) vs ($1.11) last yearMarch 27, 2025 | markets.businessinsider.com2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | businesswire.com2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14, 2025 | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14, 2025 | businesswire.comBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMarch 13, 2025 | msn.comSee More Headlines TSVT Stock Analysis - Frequently Asked Questions How have TSVT shares performed this year? 2seventy bio's stock was trading at $2.94 at the beginning of the year. Since then, TSVT shares have increased by 70.1% and is now trading at $5.00. View the best growth stocks for 2025 here. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) released its earnings results on Wednesday, May, 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.11. The company earned $22.94 million during the quarter, compared to analyst estimates of $13.96 million. 2seventy bio had a negative net margin of 207.25% and a negative trailing twelve-month return on equity of 53.65%. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 2seventy bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings5/07/2025Today7/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSVT CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees440Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$217.57 million Net Margins-207.25% Pretax Margin-207.25% Return on Equity-53.65% Return on Assets-23.67% Debt Debt-to-Equity RatioN/A Current Ratio4.95 Quick Ratio4.95 Sales & Book Value Annual Sales$48.37 million Price / Sales5.50 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.99Miscellaneous Outstanding Shares53,230,000Free Float47,874,000Market Cap$266.15 million OptionableOptionable Beta1.04 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:TSVT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.